

20  
**CLAIMS**

1. A combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof.
2. A combination according to claim 1 wherein the CDK inhibitor is an inhibitor of CDK2 or CDK4.
3. A combination according to claim 1 or claim 2 wherein the CDK inhibitor is selected from rosovitive, purvalanol A, purvalanol B and olomoucine.
4. A combination according to any preceding claim wherein the CDK inhibitor is roscovitive.
5. A combination according to any preceding claim wherein the metabolite is 1-(2-C-Cyano-2-deoxy- $\beta$ -D-arabino-pentafuranosyl)-cytosine.
6. A pharmaceutical composition comprising a combination according to any preceding claim and a pharmaceutically acceptable carrier, diluent or excipient.
7. Use of a combination according to any one of claims 1 to 5 in the preparation of a medicament for the treatment of a proliferative disorder.
8. A pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy.
9. A pharmaceutical product according to claim 8 wherein the CDK inhibitor is an inhibitor of CDK2 or CDK4.
10. A pharmaceutical product according to claim 8 or claim 9 wherein the CDK inhibitor is selected from rosovitive, purvalanol A, purvalanol B and olomoucine.

11. A pharmaceutical product according to any one of claims 8 to 10 wherein the CDK inhibitor is roscovitine.
12. A pharmaceutical product according to any one of claims 8 to 11 in the form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient.
13. A pharmaceutical product according to any one of claims 8 to 11 for use in the treatment of a proliferative disorder.
14. A pharmaceutical product according to claim 13 wherein the proliferative disorder is cancer.
15. A pharmaceutical product according to claim 14 wherein the proliferative disorder is selected from lung cancer, prostate cancer, bladder cancer, head and neck cancer, colon cancer, sarcoma and lymphoma.
16. A pharmaceutical product according to any one of claims 8 to 15 wherein the metabolite is 1-(2-C-Cyano-2-deoxy- $\beta$ -D-arabino-pentafuranosyl)-cytosine.
17. A method of treating a proliferative disorder, said method comprising administering to a subject, simultaneously, sequentially or separately, 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, and a CDK inhibitor.
18. A method according to claim 17 which comprises administering said CDK inhibitor to a subject prior to sequentially or separately administering 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to said subject.
19. A method according to claim 17 which comprises administering 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to

a subject prior to sequentially or separately administering a CDK inhibitor to said subject.

20. A method according to any one of claims 17 to 20 wherein the CDK inhibitor is an inhibitor of CDK2 or CDK4.

21. A method according to claim 20 wherein the CDK inhibitor is selected from rosovitine, purvalanol A, purvalanol B and olomoucine.

22. A method according to claim 21 wherein the CDK inhibitor is rosovitine.

23. A method according to any one of claims 17 to 22 wherein the CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, are each administered in a therapeutically effective amount with respect to the individual components.

24. A method according to any one of claims 17 to 22 wherein the CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, are each administered in a subtherapeutic amount with respect to the individual components.

25. A method according to any one of claims 17 to 24 wherein the proliferative disorder is cancer.

26. A method according to claim 25 wherein the proliferative disorder is selected from lung cancer, prostate cancer, bladder cancer, head and neck cancer, colon cancer, sarcoma and lymphoma.

27. A method according to any one of claims 17 to 26 wherein the metabolite is 1-(2-C-Cyano-2-deoxy- $\beta$ -D-arabino-pentafuranosyl)-cytosine.

28. Use of a CDK inhibitor in the preparation of a medicament for the treatment of a proliferative disorder, wherein said treatment comprises administering to a subject simultaneously, sequentially or separately 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, and a CDK inhibitor.
29. Use of a CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof in the preparation of a medicament for treating a proliferative disorder.
30. Use of a CDK inhibitor in the preparation of a medicament for the treatment of a proliferative disorder, wherein said medicament is for use in combination therapy with 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof.
31. Use of 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, in the preparation of a medicament for the treatment of a proliferative disorder, wherein said medicament is for use in combination therapy with a CDK inhibitor.